Cantor Fitzgerald Forecasts PRE FY2026 Earnings

Prenetics Global Limited (NASDAQ:PRE) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Prenetics Global in a research note issued to investors on Friday, June 13th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($1.01) for the year. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Thursday, June 12th. The company reported ($0.80) EPS for the quarter. The company had revenue of $17.31 million during the quarter. Prenetics Global had a negative return on equity of 28.07% and a negative net margin of 115.91%.

Prenetics Global Trading Up 7.1%

NASDAQ:PRE opened at $7.51 on Monday. The stock has a market capitalization of $91.62 million, a PE ratio of -1.88 and a beta of 0.17. The firm’s 50 day moving average is $6.47 and its 200 day moving average is $5.56. Prenetics Global has a 12 month low of $3.09 and a 12 month high of $11.99.

Institutional Investors Weigh In On Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new stake in shares of Prenetics Global Limited (NASDAQ:PRE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global at the end of the most recent reporting period. 25.01% of the stock is owned by institutional investors and hedge funds.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.